Anywaine Z, Serwanga J, Ggayi AM, Abaasa AM, et al. Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial. Lancet Infect Dis 2025 Nov 11:S1473-3099(25)00565.
PMID: 41237791